The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1250 Weight Loss articles
Eli Lilly's Foundayo, a new GLP-1 weight loss pill, just received FDA approval with key advantages: take it anytime without food or water restrictions. Backed by trials showing 12% body weight loss over 72 weeks, it aims to make obesity treatment more accessible. Compare pricing, side effects, and how it stacks up against Wegovy and injectables.
Eli Lilly's shares surged more than 5% following FDA approval of Foundayo, its new once-daily GLP-1 weight-loss pill that can be taken anytime without food restrictions. This oral option intensifies competition with Novo Nordisk's Wegovy and Ozempic, offering real-world convenience for overweight adults. Discover the trial results, comparisons, and implications for obesity treatment.
The Government of India has issued comprehensive guidelines on GLP-1 drugs, addressing their use for type 2 diabetes and obesity, associated risks, and regulatory measures. With drugs like semaglutide and tirzepatide gaining popularity, authorities warn against unsupervised use due to serious side effects like pancreatitis. Strict surveillance ensures prescriptions only by specialists like endocrinologists.
Health Secretary RFK Jr. hinted at FDA easing restrictions on popular peptides like BPC-157 and ipamorelin during a Joe Rogan podcast. Wellness fans hope for access from ethical suppliers, but experts warn of black market dangers. Discover the regulatory shift's potential impact on peptide therapy.
Eli Lilly is leveraging artificial intelligence to find its next big breakthrough after the GLP-1 boom transformed diabetes and obesity treatment. With rivals like Novo Nordisk in hot pursuit, Lilly's AI investments promise faster drug discovery and smarter clinical trials. This strategic shift could diversify revenue and bring new options to patients sooner.
Novo Nordisk has launched a new subscription program for Wegovy, promising up to $1,200 in yearly savings on injections to help patients maintain access to this GLP-1 obesity drug. With plans starting at $249 per month for 12 months, it targets self-pay users facing cost uncertainty. But eligibility limits mean it's not for everyone—here's what you need to know.
Hims & Hers shares surged Monday after HHS Secretary Robert F. Kennedy Jr. expressed urgency on the Joe Rogan Experience to make 14 peptides more accessible. He highlighted FDA's review of the science behind these GLP-1 active ingredients for diabetes and weight loss. This could signal easing regulatory headwinds for telehealth providers like Hims.
West Pharmaceuticals is expanding its Dublin manufacturing site, adding 330 high-skilled jobs to meet surging demand for drug delivery solutions in diabetes and obesity treatments. The 165,000 square foot facility upgrade focuses on containment and delivery systems for injectables, including next-generation GLP-1 therapies like those used in semaglutide drugs. This move strengthens Ireland's role in global metabolic health supply chains.
Boston-based Kailera Therapeutics is gearing up for an IPO to fuel its obesity drug pipeline, including Phase III GLP-1/GIP agonist ribupatide. Backed by $400M Series A and $600M Series B, the company eyes superior profiles versus blockbusters like Zepbound. Despite $368.7M deficits, topline data looms large.
